___

• 1. Robetoyre RS, Rodgers GM. Update on selected inherited venous thrombotic disorders. Am J Hematol 2001; 68: 256-68.
• 2. Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001; 109: 369-84.
• 3. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001; 86: 395-403.
• 4. Souto JC, Almasy L, Borrell M, et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: The GAIT study. Genetic analysis of idiopathic thrombophilia. Am J Hum Genet 2000; 67: 1452-9.
• 5. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 6. Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: Molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995; 85: 3405-11.
• 7. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
• 8. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thrombolism screenin. JAMA 1997; 277: 1305-7.
• 9. Akar N, Akar E, Dalgın G, et al. Frequency of Factor V (1691 G --> A) mutation in Turkish population. Thromb Haemost 1997; 78: 1527-8.
• 10. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
• 11. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
• 12. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
• 13. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
• 14. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
• 15. Martinelli I, Landi G, Merati G, et al. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1996; 75: 393-4.
• 16. de Moerloose P, Wutschert R, Heinzmann M, et al. Superficial vein thrombosis of lower limbs: Influence of factor V Leiden, factor II G20210A and overweight. Thromb Haemost 1998; 80: 239-41.
• 17. Margaglione M, Brancaccio V, De Lucia D, et al. Inherited thrombophilic risk factors and venous thromboembo lism: Distinct role in peripheral deep venous thrombosis and pulmonary embolism. Chest 2000; 118: 1405-11.
• 18. Martinelli I, Cattaneo M, Panzeri D, Mannucci PM. Low prevalence of factor V: Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost 1997; 77: 440-3.
• 19. Ridker PM, Miletich JP, Stamfer MJ, et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2.
• 20. Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
• 21. Rintelen C, Pabinger I, Knobl P, et al. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996; 75: 229-32.
• 22. Simioni P, Prandoni P, Lensing AW, et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood 2000; 96: 3329-33.
• 23. Nguyen A. Prothrombin G20210A polymorphism and thrombophilia. Mayo Clin Proc 2000; 75: 595-604.
• 24. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
• 25. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706-8.
• 26. Nguyen A. Prothrombin G20210A polymorphism and thrombophilia. Mayo Clin Proc 2000; 75: 595-604.
• 27. Cumming AM, Keeney S, Salden A, et al. The prothrombin gene G20210A variant: Prevalence in a UK anticoagulant clinic population. Br J Haematol 1997; 98: 353-5.
• 28. Hillarp A, Zoller B, Svensson PJ, Dahlback B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 1997; 78: 990-2.
• 29. Brown K, Luddington R, Williamson D, et al. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3’-untranslated region of the prothrombin gene. Br J Haematol 1997; 98: 907-9.
• 30. Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G- ->A20210 gene variant. Ann Intern Med 1998; 129: 89-93.
• 31. Lindmarker P, Schulman S, Sten-Linder M, et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 1999; 81: 684-9.
• 32. Martinelli I, Bucciarelli P, Margaglione M, et al. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000; 111: 1223-9.
• 33. Makris M, Preston FE, Beauchamp NJ, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 1997; 78: 1426-9.
• 34. Gemmati D, Serino ML, Moratelli S, et al. Coexistence of factor V G1691A and factor II G20210A gene mutations in a thrombotic family is associated with recurrence and early onset of venous thrombosis. Haemostasis 2001; 31: 99-105.
• 35. Bertina RM. Molecular risk factors for thrombosis. Thromb Haemost 1999; 82: 601-9.
• 36. Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311: 1525-8.
• 37. Schwarz HP, Fischer M, Hopmeier P, et al. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64: 1297-300.
• 38. Ploos van Amstel JK, van der Zanden AL, Bakker E, et al. Two genes homologous with human protein S cDNA are located on chromosome 3. Thromb Haemost 1987; 58: 982-7.
• 39. Gandrille S, Borgel D, Sala N, et al. Protein S deficiency: A database of mutations--summary of the first update. Thromb Haemost 2000; 84: 918.
• 40. Dykes AC, Walker ID, McMahon AD, et al. A study of protein S antigen levels in 3788 healthy volunteers: Influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001; 113: 636-41.
• 41. Koeleman BP, van Rumpt D, Hamulyak K, et al. Factor V Leiden: An additional risk factor for thrombosis in protein S deficient families? Thromb Haemost 1995; 74: 580-3.
• 42. Zoller B, Berntsdotter A, Garcia de Frutos P, Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
• 43. Middeldorp S, Henkens CM, Koopman MM, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128: 15-20.
• 44. Greaves M, Baglin T. Laboratory testing for heritable thrombophilia: Impact on clinical management of thrombotic disease annotation. Br J Haematol 2000; 109: 699-703.
• 45. Baglin T. Thrombophilia testing: What do we think the tests mean and what should we do with the results? J Clin Pathol 2000; 53: 167-70.
• 46. Margaglione M, D’Andrea G, Colaizzo D, et al. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost 1999; 82: 1583-7.